Category: Artificial Intelligence

Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.

Samuel D. Warren and Louis D. Brandeis’ 1890 article “The Right To Privacy” has become classic reading for 21st century data professionals. But as we discovered in an excellent webinar with Denise Farnsworth Chief Privacy Officer, and Senior Corporate Counsel at Jazz Pharmaceuticals, Brandeis’ article forms only half of the data privacy story. What data […]

The approach towards data privacy in the EU makes consideration towards consent revocation an imperative. If a physician revokes consent, individual versus aggregate spend figures need to be recalculated, and they will show the corresponding changes. Thus, historical consent rate figures may not be an accurate indicator of transparency in that specific market or even […]

Physician consent can be a contentious issue. Especially when data privacy interpretation comes into play. In a webinar we hosted, Brian Sharkey, VP of Porzio Life Sciences LLC, raised a question about the validity of consent rates as an indicator of pharmaceutical transparency. So, is there a direct correlation between transparency in the pharmaceutical sector […]

How stringent are pharmaceutical disclosure requirements in your country? Depends on who you’re asking. Team qordata invited Brian Sharkey, Vice President of Porzio Life Sciences LLC, to host our webinar on “EFPIA Reporting and Consent Management”. What he had to say pretty much confirms that when it comes to compliance disclosure, context is key. Some […]

In qordata’s most recent post: A Quick Quiz To Check Your Compliance Analytics Acumen, Zafar Ahmed quotes Ishita Arora on realistic scope assumptions to make when designing one’s compliance/transparency program. We take that discussion a little further today by discussing how to better organize the pharma compliance workflow by dividing it in two phases: Reporting […]

Still unsure about introducing a compliance analytics program into your company? You’re not alone. Of the 9272* medical drug and device companies in the USA, only 1,481 submitted their CMS report in 2016, down from 1,579 in 2015. While for some, macro issues like M&A and CIAs may explain the lack of a report, other […]